Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage (NEWTON2)
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
Sponsor: Edge Therapeutics Inc
Terminated
DMC review concluded study has a low probability of meeting its primary endpoint
Other terminated trials from Edge Therapeutics Inc
More terminations from Edge Therapeutics Inc
Listed as NCT02790632, this PHASE3 trial focuses on Subarachnoid Hemorrhage, Aneurysmal and remains terminated or withdrawn. Sponsored by Edge Therapeutics Inc, it has been updated 18 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
▶ Show 13 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Edge Therapeutics Inc
For direct contact, visit the study record on ClinicalTrials.gov .